Skip to content

Insulin HYE-5361Recalls & reported problems

DRG Instruments Gesellschaft mit beschränkter Haftung · The DRG:HYBRId-XL Insulin is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Insulin in serum and plasma (EDTA and Heparin). · Class 1

Data updated Oct 16, 2026 from official FDA records · Editorial policy

1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.

Adverse event reports
0
Deaths reported
0
Injuries reported
0
Recalls naming it
1

Summary

No MAUDE adverse event reports in our data reference this device identifier directly.

1 FDA recall record name this device's identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Recalls naming this device

  1. Oct 7, 2024Open, Classified

    The user of the assay may either face a failure message during re-calibration of the Hybrid.XL instrument using the re-calibration R1 and R2 of the device or find controls out of specification (failed Control High) which causes a delay in results.

    Z-0921-2025 · Root cause: Nonconforming Material/Component · Recall details · FDA record ↗

Other Radioimmunoassay, Immunoreactive Insulin devices

All Radioimmunoassay, Immunoreactive Insulin devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page